We are live on ! Find out more
MCRB icon

Seres Therapeutics

60 hedge funds and large institutions have $409M invested in Seres Therapeutics in 2015 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 14 increasing their positions, 7 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

158,200% more call options, than puts

Call options by funds: $1.58M | Put options by funds: $1K

250% more capital inflows, than outflows

Capital inflows: $138M | Capital outflows: $39.4M

100% more repeat investments, than reductions

Existing positions increased: 14 | Existing positions reduced: 7

88% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 16

33% more funds holding

Funds holding: 45 → 60 (+15)

6.15% more ownership

Funds ownership: 29.21% → 35.36% (+6.2%)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

Holders
60
Holders Change
+15
Holders Change %
+33.33%
% of All Funds
1.67%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
30
Increased
14
Reduced
7
Closed
16
Calls
$1.58​M
Puts
$1​K
Net Calls
+$1.58​M
Net Calls Change
+$1.58​M

MCRB Hedge Fund Activity: Q3 2015 in Review

60 of the 3,589 institutional investors tracked by Wall St. Rank reported a position in Seres Therapeutics (MCRB) for Q3 2015, worth a combined $409M — down 13% from $471M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new MCRB positions and 16 closed out — a net gain of 14 holders — while 14 added to existing stakes and 7 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $24.7M. The largest seller was BlackRock Advisors, cutting an estimated $12.6M.

  • 60 institutional investors held Seres Therapeutics (MCRB) as of Q3 2015, up from 45 in Q2 2015.
  • Funds reported $409M of Seres Therapeutics stock for Q3 2015, down 13% quarter-over-quarter.
  • 30 funds opened new Seres Therapeutics positions in Q3 2015 and 16 closed out, a net change of +14 holders.
  • The largest Seres Therapeutics buyer in Q3 2015 was Fidelity Investments, an estimated $24.7M added.
  • The largest Seres Therapeutics seller in Q3 2015 was BlackRock Advisors, an estimated $12.6M sold.

Based on aggregated 13F filings for Q3 2015.